论文部分内容阅读
目的探讨小剂量阿糖胞苷、阿克拉霉素和粒细胞集落刺激因子联合治疗骨髓增生异常综合征(MDS)转化急性白血病的临床疗效。方法选取2005年3月至2014年3月间江苏省南通市如东县人民医院血液内科收治的122例MDS转化的急性白血病患者,采用随机数字表法随机分为观察组和对照组,每组61例。观察组患者采用小剂量阿糖胞苷、阿克拉霉素和粒细胞集落刺激因子联合治疗,对照组患者采用常规化疗治疗,比较两组患者的临床疗效。结果观察组患者治疗的总有效率为90.2%(55/61),显著高于对照组的70.5%(43/61),差异有统计学意义(P<0.05)。观察组患者的不良反应发生率为14.8%(9/61),显著低于对照组的41.0%(25/61),差异有统计学意义(P<0.05)。结论小剂量阿糖胞苷、阿克拉霉素和粒细胞集落刺激因子联合治疗MDS转化的急性白血病的临床疗效较常规化疗治疗好,且具有较高的安全性。
Objective To investigate the clinical efficacy of low dose of cytarabine, aclacinomycin and granulocyte colony-stimulating factor in the treatment of myelodysplastic syndrome (MDS) in the treatment of acute leukemia. Methods A total of 122 MDS-transformed acute leukemia patients admitted to Department of Hematology, Rudong People’s Hospital, Nantong City, Jiangsu Province from March 2005 to March 2014 were randomly divided into observation group and control group with random number table, and each group 61 cases. Patients in the observation group were treated with low dose of cytarabine, aclacinomycin and granulocyte colony-stimulating factor, and patients in the control group were treated with conventional chemotherapy. The clinical efficacy of the two groups were compared. Results The total effective rate of observation group was 90.2% (55/61), which was significantly higher than that of control group (70.5%, 43/61). The difference was statistically significant (P <0.05). The incidence of adverse reactions in the observation group was 14.8% (9/61), which was significantly lower than that in the control group (41.0%, 25/61). The difference was statistically significant (P <0.05). Conclusion The combination of low dose of cytarabine, aclacinomycin and granulocyte colony-stimulating factor in the treatment of acute leukemia with MDS is better than conventional chemotherapy and has high safety.